Trial · NCT01423188
The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
NCT01423188, Phase 2, Completed, Resverlogix Corp
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation. Trials, record NCT01423188. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01423188
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
- NCT number
- NCT01423188
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 176 participants, actual
- Lead sponsor
- Resverlogix Corp
- Conditions
- Coronary Artery Disease, Dyslipidemia
- Interventions
- RVX000222, Placebo RVX000222
- First posted
- 2011-08-25
- Last updated
- 2012-09-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The percent change in HDL-C from baseline to 24 weeks for RVX000222 200 mg daily compared to placebo | 24 weeks | To determine whether treatment with RVX000222 produces an increase in HDL-C at 24 weeks compared to placebo. |
| Secondary | Within treatment group percent change in HDL-C from baseline to 24 weeks for RVX000222 and placebo groups. | 24 weeks | To evaluate changes in other lipids such as HDL-C, LDL-C, non-HDL-C, apoB, TG and HDL subclasses over time within and between treatment groups. |
| Secondary | The percent change in plasma apoA-I from baseline to 4 weeks, 12 weeks and 24 weeks for RVX000222 compared to placebo (within and between treatment groups). | 4, 12 and 24 weeks | To evaluate changes in plasma levels of apoA-I over time within and between treatment groups. |
| Secondary | The percent change in LDL-C, non-HDL-C, apoB, TG and HDL subclasses from baseline to 4 weeks, 12 weeks and 24 weeks for RVX000222 compared to placebo (within and between treatment groups) | 4, 12 and 24 weeks | To evaluate changes in other lipids such as HDL-C, LDL-C, non-HDL-C, apoB, TG and HDL subclasses over time within and between treatment groups. |
| Secondary | Incidence of adverse events by treatment group | Participants will be followed for the duration of the study: 30 weeks (2 weeks screening, 24 weeks active treatment, 4 week follow-up) | To evaluate the safety and tolerability of RVX000222. |
| Secondary | The percent change in HDL-C from baseline to 4 weeks and 12 weeks for RVX000222 compared to placebo (within and between treatment groups) | 4, 12 weeks | To evaluate changes in other lipids such as HDL-C, LDL-C, non-HDL-C, apoB, TG and HDL subclasses over time within and between treatment groups. |
| Secondary | The percent change in hsCRP from baseline to 12 weeks and 24 weeks for RVX000222 compared to placebo (within and between treatment groups). | 12, 24 weeks | To evaluate changes in hs-CRP over time within and between treatment groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22349989 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01423188
GET https://conductscience.org/api/trials/v1/NCT01423188/registered